PBLSParabilis Medicines, Inc.
$27.53
$27.53
$25.0152 weeks$41.68
PBLS in its own filings
Nothing in PBLS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
6
Events found in the filings · across 62 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 15, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 11, 2026
Record starts · the earliest filing Ryufin holds for this name
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Officer, mutually agreed that Dr. Benzaghou would transition from the Company effective as of September 30, 2026.Director or officer change · Form 8-K
- Aug 25, 2026On August 22, 2026, the Board of Directors (the “Board”) of Parabilis Medicines, Inc. (the “Company”) increased the number of directors of the Company to nine (9) and appointed Craig Tendler as a director of the Company to fill the newly created vacancy.Director or officer change · Form 8-K
- Aug 13, 2026Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jun 11, 2026On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry